Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SELECTA BIOSCIENCES, INC.

(SELB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Selecta Biosciences, Swedish Orphan Biovitrum Complete Enrollment in Phase 3 SEL-212 Study For Gout Treatment

12/01/2021 | 11:08am EST


© MT Newswires 2021
All news about SELECTA BIOSCIENCES, INC.
01/10Health Care Stocks Return to Positive Ground This Afternoon
MT
01/10Health Care Stocks Edging Lower in Monday Afternoon Trading
MT
01/10Selecta Biosciences Collaborates with Ginkgo Bioworks to Develop Gene Therapy Viral Cap..
MT
01/10SELECTA BIOSCIENCES INC : Other Events (form 8-K)
AQ
01/10Selecta Biosciences and Ginkgo Bioworks Announce New Collaboration to Develop Next-Gene..
CI
01/05Selecta Biosciences to Participate at the 2022 H.C. Wainwright BioConnect Conference
AQ
2021Selecta Biosciences to Participate at the LifeSci Partners 11th Annual Corporate Access..
GL
2021Thinking about buying stock in Intra-Cellular Therapies, Selecta Biosciences, Coherus B..
PR
2021SELECTA BIOSCIENCES, INC.(NASDAQGM : SELB) dropped from S&P Biotechnology Select Industry ..
CI
2021INSIDER BUY : Selecta Biosciences
MT
More news
Analyst Recommendations on SELECTA BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 68,4 M - -
Net income 2021 -45,1 M - -
Net Debt 2021 - - -
P/E ratio 2021 -6,25x
Yield 2021 -
Capitalization 292 M 292 M -
Capi. / Sales 2021 4,26x
Capi. / Sales 2022 6,90x
Nbr of Employees 44
Free-Float 68,2%
Chart SELECTA BIOSCIENCES, INC.
Duration : Period :
Selecta Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SELECTA BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 2,50 $
Average target price 8,83 $
Spread / Average Target 253%
EPS Revisions
Managers and Directors
Carsten Brunn President, Chief Executive Officer & Director
Kevin Tan Chief Financial & Accounting Officer
Carrie Smith Cox Chairman
Lloyd Johnston COO, Senior Vice President-Research & Development
Takashi Kei Kishimoto Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
SELECTA BIOSCIENCES, INC.-22.39%295
GILEAD SCIENCES, INC.-4.88%86 640
REGENERON PHARMACEUTICALS-2.12%64 627
VERTEX PHARMACEUTICALS5.12%58 692
WUXI APPTEC CO., LTD.-6.39%51 406
BIONTECH SE-37.29%39 044